MBS498 - How to solve endometriosis problems for 190 million women - Somer Baburek, CEO Herabiotech (Built in Texas #3)

Send us a text

Hera began operations in January of 2020 as a Delaware “C” Corporation with headquarters in San Antonio, TX. Hera’s initial goal is to commercialize the MetriDx™, a novel, non-surgical method for the definitive and early diagnosis of endometriosis. Endometriosis is defined as the presence of endometrial glands and stromal-like lesions outside of the uterus.

Endometriosis affects 10-20% of all women of reproductive age; 7-13 million in the US alone. Current diagnosis of endometriosis is by visualization during laparoscopic surgery, confirmed by histological pathology, performed under general anesthesia by a surgeon or gynecologist. 

The surgical methodology suffers from being highly site specific, depending on the experience of the surgeon, failure to detect lesions in ~16% of cases and almost half of all biopsies are negative.

Alternatively, many physicians choose to diagnose the disease empirically or, without a definitive diagnosis; this results in multiple “trial & error” interventions, increased liability risk and patient frustration. In most cases, patients suffer between 7-12 years with intense pain before a diagnosis is given and interventions are administered, with 68% of women with endometriosis being misdiagnosed with another condition prior to receiving the correct diagnosis.

Get interviewed on the Matt Brown Show: www.mattbrownshow.com

Support the show